Introduction {#imm12993-sec-0001}
============

Interleukin‐17A (IL‐17A, called 'IL‐17' hereafter) is a member of the IL‐17 family.[1](#imm12993-bib-0001){ref-type="ref"} The binding of IL‐17 to the heterodimeric receptor consisting of IL‐17RA and IL‐17RC subunits transduces signals to activate a group of cytokines and chemokines such as tumour necrosis factor, IL‐1, IL‐6, granulocyte colony‐stimulating factor, CXCL1 and CXCL2 through activation of the actin related gene 1‐TNF receptor associated factor 6--nuclear factor‐*κ*B axis in the downstream.[1](#imm12993-bib-0001){ref-type="ref"} The function of IL‐17 is pleiotropic. It plays a crucial role in the host defence against bacterial and fungal infection by inducing pro‐inflammatory cytokines and chemokines, recruiting neutrophils, and activating T cells and B cells.[1](#imm12993-bib-0001){ref-type="ref"}, [2](#imm12993-bib-0002){ref-type="ref"} Mice deficient for IL‐17RA are highly susceptible to *Klebsiella pneumoniae* [3](#imm12993-bib-0003){ref-type="ref"} and IL‐17‐deficient mice are susceptible to bacterial and fungal infection.[4](#imm12993-bib-0004){ref-type="ref"}, [5](#imm12993-bib-0005){ref-type="ref"} Interleukin‐17 is also implicated in various inflammatory/autoimmune disease models such as experimental autoimmune encephalomyelitis (EAE), arthritis in IL‐1 receptor antagonist‐deficient *(Il1rn* ^--/--^) mice and imiquimod‐induced psoriatic dermatitis in mice.[6](#imm12993-bib-0006){ref-type="ref"}, [7](#imm12993-bib-0007){ref-type="ref"}, [8](#imm12993-bib-0008){ref-type="ref"}, [9](#imm12993-bib-0009){ref-type="ref"}, [10](#imm12993-bib-0010){ref-type="ref"} Anti‐IL‐17 and anti‐IL‐17RA antibodies are effective to treat patients with psoriasis and psoriatic arthritis.[11](#imm12993-bib-0011){ref-type="ref"}, [12](#imm12993-bib-0012){ref-type="ref"}, [13](#imm12993-bib-0013){ref-type="ref"} Interleukin‐17 is also important for the maintenance of intestinal barrier integrity and its functional deficiency causes the development of inflammatory bowel diseases.[14](#imm12993-bib-0014){ref-type="ref"}, [15](#imm12993-bib-0015){ref-type="ref"}, [16](#imm12993-bib-0016){ref-type="ref"} In contrast, suppression of IL‐17F, another highly homologous member of IL‐17 family, is suggested to be beneficial for the treatment of inflammatory bowel diseases.[17](#imm12993-bib-0017){ref-type="ref"}

Interleukin‐17 was initially found to be produced by helper CD4^+^ T \[T helper type 17 (Th17)\] cells, but subsequent studies showed that innate immune cells and innate‐like immune cells are also important sources of IL‐17 in inflamed tissues.[18](#imm12993-bib-0018){ref-type="ref"}, [19](#imm12993-bib-0019){ref-type="ref"} *γδ* T cells are the principal source of IL‐17 in some mouse inflammatory disease models and thereby exert considerable impact on disease development and progression.[20](#imm12993-bib-0020){ref-type="ref"}, [21](#imm12993-bib-0021){ref-type="ref"}, [22](#imm12993-bib-0022){ref-type="ref"}, [23](#imm12993-bib-0023){ref-type="ref"}, [24](#imm12993-bib-0024){ref-type="ref"} The IL‐17‐producing *γδ* T cells (*γδ*17 cells) share many features with Th17 cells, such as cell surface expression of IL‐23R and CCR6 and the expression of transcriptional factor retinoic‐acid‐receptor‐related orphan receptor *γ*t (ROR*γ*t). To induce IL‐17, naive T cells have to differentiate into Th17 cells in the periphery by the stimulation with T‐cell receptor (TCR) and cytokines such as IL‐6 and transforming growth factor‐*β*. In contrast, the functional potential to produce IL‐17 in *γδ*17 cells is already established during intra‐thymic development[25](#imm12993-bib-0025){ref-type="ref"}, [26](#imm12993-bib-0026){ref-type="ref"}, [27](#imm12993-bib-0027){ref-type="ref"} and IL‐17 is directly induced by IL‐23 and IL‐1 without TCR stimulation in the periphery. This pre‐programming contributes to rapid IL‐17 production in peripheral tissues in the early phase of pathogen infection. In this review, we would like to introduce the roles of *γδ*17 cells in inflammatory diseases and recent therapeutic advances targeting IL‐17.

*γδ* T‐cell subsets and their development {#imm12993-sec-0002}
=========================================

*γδ* T cells and *αβ* T cells are generated in thymus from common progenitor cells. Unlike *αβ* T cells, *γδ* T cells are functionally committed during intra‐thymic differentiation.[28](#imm12993-bib-0028){ref-type="ref"}, [29](#imm12993-bib-0029){ref-type="ref"} In mice, the TCR‐*γ* locus consists of seven V*γ* (V*γ*1--V*γ*7) genes (Heilig & Tonegawa\'s nomenclature[30](#imm12993-bib-0030){ref-type="ref"}) that are closely correlated with the effector function, although V*γ*3 is a pseudogene in most mouse strains.[31](#imm12993-bib-0031){ref-type="ref"} Production of IL‐17 is mostly limited to V*γ*4^+^ and V*γ*6^+^ *γδ* T cells,[32](#imm12993-bib-0032){ref-type="ref"} although V*γ*1^+^ *γδ* T cells also produce IL‐17 in some cases.[33](#imm12993-bib-0033){ref-type="ref"} On the other hand, interferon‐*γ* (IFN‐*γ*) production is associated with V*γ*1^+^, V*γ*5^+^ and V*γ*7^+^ *γδ* T cells. Although overall gene expression patterns are similar between V*γ*4^+^ and V*γ*6^+^ subsets,[34](#imm12993-bib-0034){ref-type="ref"} each subset has distinct features (Fig. [1](#imm12993-fig-0001){ref-type="fig"}). V*γ*6^+^ *γδ* T cells express the invariant V*γ*6/V*δ*1 TCR, develop only in the late embryonic thymus and preferentially localize to the uterus, vagina, lung, dermis and peritoneal cavity.[35](#imm12993-bib-0035){ref-type="ref"}, [36](#imm12993-bib-0036){ref-type="ref"} On the other hand, V*γ*4^+^ *γδ* T cells develop in both fetal and adult thymus, have more diverse TCR repertoire and reside in the dermis, lung, liver and secondary lymphoid organs.[37](#imm12993-bib-0037){ref-type="ref"}, [38](#imm12993-bib-0038){ref-type="ref"} In addition to ROR*γ*t, transcription factors such as Blk,[39](#imm12993-bib-0039){ref-type="ref"} Hes‐1,[40](#imm12993-bib-0040){ref-type="ref"} nuclear factor‐*κ*B,[41](#imm12993-bib-0041){ref-type="ref"} Sox4 and Sox13[42](#imm12993-bib-0042){ref-type="ref"} are also important for γδ17 cell development. Transforming growth factor‐*β* and IL‐7 are required for *γδ*17 thymocyte development and expansion, respectively.[43](#imm12993-bib-0043){ref-type="ref"}, [44](#imm12993-bib-0044){ref-type="ref"}, [45](#imm12993-bib-0045){ref-type="ref"} Epigenetic and transcriptional regulation during *γδ*17 cell differentiation has been reviewed elsewhere.[46](#imm12993-bib-0046){ref-type="ref"} *γδ* thymocytes capable of producing IL‐17, which express the transcription factor ROR*γ*t and the signature cytokine receptor IL‐23R,[34](#imm12993-bib-0034){ref-type="ref"} leave the thymus as functionally committed cells,[47](#imm12993-bib-0047){ref-type="ref"} and produce IL‐17 directly by the stimulation with IL‐1*β* and IL‐23 in the periphery. Although IL‐23R is constitutively expressed on *γδ*17 cells, the expression of IL‐1R in peripheral *γδ*17 cells is tissue‐dependent.[48](#imm12993-bib-0048){ref-type="ref"} In addition to IL‐1R and IL‐23R, the expression of scavenger receptor 2 (Scart 2)[49](#imm12993-bib-0049){ref-type="ref"} and CCR6,[27](#imm12993-bib-0027){ref-type="ref"} and the lack of CD122[25](#imm12993-bib-0025){ref-type="ref"} and CD27 expression[26](#imm12993-bib-0026){ref-type="ref"} are often used as markers for *γδ*17 cells, with the exception for IL‐17‐producing V*γ*1^+^ *γδ* T cells.[33](#imm12993-bib-0033){ref-type="ref"} These phenotypes, established during thymic development, distinguish *γδ*17 cells from IFN‐γ‐producing *γδ* T (*γδ*IFN‐*γ*) cells (Fig. [2](#imm12993-fig-0002){ref-type="fig"}). *γδ*17 cells that develop before birth persist in adult mice as self‐renewing, long‐lived cells.[50](#imm12993-bib-0050){ref-type="ref"}

![Distinct features of *γδ*17 cell subset and suggested model of 'natural' *γδ*17 cells versus 'inducible' *γδ*17 cells. V*γ*6^+^ *γδ* T cells express the invariant V*γ*6/V*δ*1 T‐cell receptor (TCR), develop only in the late embryonic thymus, and preferentially localize to the uterus, vagina, lung, dermis and peritoneal cavity. On the other hand, V*γ*4^+^ *γδ* T cells develop in both fetal and adult thymus and have a more diverse TCR repertoire. These cells circulate in blood and reside in the dermis, lung, liver and secondary lymphoid organs. In according to Haas *et al*.[50](#imm12993-bib-0050){ref-type="ref"} 'natural' *γδ*17 cells (V*γ*6^+^ and part of V*γ*4^+^) developed before birth acquire interleukin‐17 (IL‐17) ‐producing ability in thymus and produce IL‐17 stimulated by IL‐1*β* and IL‐23 in the periphery. Conversely, IL‐17 production induced by TCR signalling was also reported.[56](#imm12993-bib-0056){ref-type="ref"} Naive *γδ* T cells developed after birth may egress the thymus as 'inducible' *γδ*17 cells (mostly V*γ*4^+^) and differentiate to produce IL‐17 after encounter with antigen.](IMM-155-418-g001){#imm12993-fig-0001}

![Characterization of *γδ*17cells. *γδ*17 cells have some distinct phenotypes and are distinguished from interferon‐*γ* (IFN‐*γ*)‐producing *γδ* T cells ; *γδ*17 cells express interleukin‐1 receptor (IL‐1R), IL‐23R, IL‐7R, CCR2, CCR6, CD44 and Scart2 on the cell surface. The transcriptional factors of RORγt, Blk, Hes‐1, NF‐κB, Sox4 and Sox13 are important for *γδ*17 development. On the other hand, IFN‐*γ*‐producing *γδ* T cells express CD27, CD122 and NK1.1. These phenotypes are established during thymic development.](IMM-155-418-g002){#imm12993-fig-0002}

The requirement of TCR signalling for *γδ*17 cell development is not fully understood.[51](#imm12993-bib-0051){ref-type="ref"} Early T‐cell precursors can produce IL‐17 before TCR recombination[50](#imm12993-bib-0050){ref-type="ref"} and Sox4 and Sox13 are expressed before activation with TCR signalling.[42](#imm12993-bib-0042){ref-type="ref"} Antigen‐naive *γδ* T cells in the thymus differentiate into IL‐17 producers, whereas antigen‐experienced cells make IFN‐*γ*.[28](#imm12993-bib-0028){ref-type="ref"} Furthermore, V*γ*5^+^V*δ*1^+^ thymocytes induce Egr3 upon recognition of Skint‐1 expressed on thymic epithelial cells, resulting in the induction of IFN‐*γ* expression and suppression of ROR*γ*t and Sox13 expression.[52](#imm12993-bib-0052){ref-type="ref"} Thus, TCR signalling seems to direct *γδ* thymocytes to differentiate into IFN‐*γ*‐producing *γδ* T cells by suppressing the 'default' IL‐17 programme.

The mechanism of IL‐17 production in *γδ*17 cells {#imm12993-sec-0003}
=================================================

*γδ*17 cells are functionally committed in the thymus, producing IL‐17 in the periphery after stimulation with IL‐1*β* and IL‐23 without additional TCR stimulation.[21](#imm12993-bib-0021){ref-type="ref"}, [24](#imm12993-bib-0024){ref-type="ref"} The 'ready‐to‐go' phenotype of *γδ*17 cells is especially efficient for early‐stage pathogen clearance. A combination of IL‐1*β* and IL‐23, but not IL‐1*β* or IL‐23 alone, is required to induce IL‐17 by *γδ*17 cells.[20](#imm12993-bib-0020){ref-type="ref"} Further study revealed that IL‐23 is required for the induction of IL‐1R, and IL‐1*β* is essential for the induction of IL‐17.[20](#imm12993-bib-0020){ref-type="ref"} However, because IL‐1*β* alone does not induce IL‐17 production in *Il1rn* ^−/−^ mouse‐derived splenic *γδ* T cells[20](#imm12993-bib-0020){ref-type="ref"} and in normal peritoneum‐ and lung‐derived *γδ* T cells, in which high levels of IL‐1R are expressed,[48](#imm12993-bib-0048){ref-type="ref"} IL‐23 may play other roles than up‐regulating IL‐1R in the induction of IL‐17 expression in *γδ* T cells. In this context, ROR*γ*t expression is up‐regulated by IL‐1*β* and IL‐23 in a synergistic manner.[20](#imm12993-bib-0020){ref-type="ref"} The inflammatory cytokine IL‐18,[53](#imm12993-bib-0053){ref-type="ref"} complement C5a,[54](#imm12993-bib-0054){ref-type="ref"} the ligand of Toll‐like receptors 1 and 2, and dectin‐1[55](#imm12993-bib-0055){ref-type="ref"} also induce IL‐17 in collaboration with IL‐23. Although *γδ*17 cells typically behave as innate‐like immune cells, IL‐17 induction by TCR signalling is also reported. Mouse and human *γδ* T cells recognize an algal protein, phycoerythrin, and differentiate to IL‐17‐producing cells after immunization by this antigen.[56](#imm12993-bib-0056){ref-type="ref"} These studies, in combination with cell reconstitution studies,[50](#imm12993-bib-0050){ref-type="ref"} suggest that 'natural' *γδ*17 cells (V*γ*6^+^ and part of V*γ*4^+^) acquire IL‐17‐producing ability in the fetal thymus and do not require TCR stimulation in the periphery, whereas 'inducible' *γδ*17 cells (mostly V*γ*4^+^) that develop after birth produce IL‐17 upon encounter with antigens[57](#imm12993-bib-0057){ref-type="ref"} (Fig. [1](#imm12993-fig-0001){ref-type="fig"}). Notably, phycoerythrin antigen stimulation induces IL‐1R expression on *γδ* T cells.[56](#imm12993-bib-0056){ref-type="ref"} Therefore, *γδ* TCR activation may make 'inducible' *γδ*17 cells respond to IL‐1*β* and IL‐23 to induce IL‐17. A similar activation mechanism is also suggested in Th17 cell differentiation; IL‐1R expression is increased upon Th17 differentiation from naive CD4^+^ T cells,[58](#imm12993-bib-0058){ref-type="ref"} and the polarized Th17 cells can produce IL‐17 by IL‐1 and IL‐23 in the absence of TCR stimulation.[59](#imm12993-bib-0059){ref-type="ref"} However, the molecular basis for the 'inducible' state and the difference between 'naive' and 'inducible' *γδ*17 cells remain to be elucidated.

The pathogenic roles of *γδ*17 cells in mouse inflammatory disease models {#imm12993-sec-0004}
=========================================================================

*Il17* ^--/--^ mice show significantly reduced severity in various inflammatory and autoimmune disease models, such as collagen‐induced arthritis,[6](#imm12993-bib-0006){ref-type="ref"} *Il1rn* ^−/−^ mouse arthritis,[7](#imm12993-bib-0007){ref-type="ref"} EAE[8](#imm12993-bib-0008){ref-type="ref"} and imiquimod (IMQ)‐induced skin inflammation,[9](#imm12993-bib-0009){ref-type="ref"}, [10](#imm12993-bib-0010){ref-type="ref"} suggesting critical roles of IL‐17 in inflammatory/autoimmune diseases. *γδ*17 cells are detected in inflamed tissues of these disease models. However, the roles of *γδ* T cells in the development of diseases and the responsible *γδ* subset are different in different models (Table [1](#imm12993-tbl-0001){ref-type="table"}). As no conditional *Il17* ^--/--^ mice in which the *Il17* gene is deleted specifically in *γδ*17 cells are available, the pathogenicity of *γδ*17 cells has been analyzed using *γδ* T‐cell‐deficient mice (*Tcrd* ^‐/‐^ mice) or the *γδ*17 cell subset from these disease models.

###### 

*γδ*17 induction and function in inflammatory disease

  Disease                                                                                     Disease model                         Dominant subset                                   Induction of *γδ*17 cells                                                                                       *γδ*17 function                                                                                     References
  ------------------------------------------------------------------------------------------- ------------------------------------- ------------------------------------------------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Rheumatoid arthritis (RA)                                                                   collagen‐induced arthritis            V*γ*4^+^ V*δ*4^+^                                 *Mycobacterium tuberculosis* components in complete Freund\'s adjuvant (CFA) or subsequent cytokine induction   Promote Th17 cells                                                                                  [22](#imm12993-bib-0022){ref-type="ref"}, [24](#imm12993-bib-0024){ref-type="ref"}, [60](#imm12993-bib-0060){ref-type="ref"}
  *Il1rn* ^−/−^ mice                                                                          V*γ*6^+ ^V*δ*1^+^                     Up‐regulation of interleuki ‐1 receptor (IL‐1R)   IL‐17‐induced hyperinflammation                                                                                 [20](#imm12993-bib-0020){ref-type="ref"}                                                            
  Spondyloarthritides (SpA)                                                                   IL‐23 overexpression                  V*γ*6^+^                                          Hyper IL‐23 induction                                                                                           IL‐17‐induced hyperinflammation                                                                     [65](#imm12993-bib-0065){ref-type="ref"}
  Multiple sclerosis (MS)                                                                     EAE                                   V*γ*4^+^                                          IL‐1β and IL‐23 from dendritic cells (DC) induced by *Mycobacterium tuberculosis* components in CFA             Promote Th17 cells, and suppress regulatory T cells                                                 [21](#imm12993-bib-0021){ref-type="ref"}, [61](#imm12993-bib-0061){ref-type="ref"}
  Uveitis                                                                                     EAU                                   V*γ*4^+^ V*δ*4^+^                                 Components in CFA or subsequent cytokine induction                                                              Promote Th17 cells                                                                                  [104](#imm12993-bib-0104){ref-type="ref"}
  Psoriasis                                                                                   IMQ                                   V*γ*4^+^ and V*γ*6^+^                             Imiquimod (IMQ)‐induced IL‐23 from DC                                                                           IL‐17 production and subsequent neutrophil inflammation                                             [9](#imm12993-bib-0009){ref-type="ref"}, [10](#imm12993-bib-0010){ref-type="ref"}, [23](#imm12993-bib-0023){ref-type="ref"}, [35](#imm12993-bib-0035){ref-type="ref"}, [42](#imm12993-bib-0042){ref-type="ref"}, [64](#imm12993-bib-0064){ref-type="ref"}
  IL‐23                                                                                                                             Hyper IL‐23 induction                             IL‐17 production and subsequent neutrophil inflammation                                                         [23](#imm12993-bib-0023){ref-type="ref"}                                                            
  Uveoretinitis in autoimmune polyendocrinopathy--candidiasis--ectodermal dystrophy (APCED)   *Aire* ^−/−^ mice                     V*γ*6^+ ^V*δ*1^+^                                 Up‐regulation of IL‐7 in the thymus                                                                             IL‐17‐induced hyperinflammation                                                                     [44](#imm12993-bib-0044){ref-type="ref"}
  Skin graft rejection                                                                        Male to female skin transplantation   V*γ*4^+^                                          Accumulation CCR6^+^ *γδ*17 cells in skin graft                                                                 IL‐17 promotes the accumulation of DC in draining lymph nodes to subsequently activate Th17 cells   [66](#imm12993-bib-0066){ref-type="ref"}
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In the collagen‐induced arthritis model, both *γδ*17 cells and Th17 cells are found in joints and draining lymph nodes and the majority of the *γδ*17 cells are V*γ*4^+^/V*δ*4^+^.[22](#imm12993-bib-0022){ref-type="ref"}, [24](#imm12993-bib-0024){ref-type="ref"} V*γ*4^+^ cell depletion reduces Th17 cell number[60](#imm12993-bib-0060){ref-type="ref"} as well as arthritis severity,[22](#imm12993-bib-0022){ref-type="ref"} suggesting that the V*γ*4^+^/V*δ*4^+^subset aggravates disease by promoting a Th17 cell response. Some components of heat‐killed *Mycobacterium tuberculosis* in complete Freund\'s adjuvant or inflammatory cytokines induced by the adjuvant are suggested to induce V*γ*4^+^/V*δ*4^+^ cell expansion.[24](#imm12993-bib-0024){ref-type="ref"}, [60](#imm12993-bib-0060){ref-type="ref"} *Il1rn* ^−/−^ mice develop arthritis spontaneously in an IL‐17‐dependent manner.[7](#imm12993-bib-0007){ref-type="ref"} In these mice, however, only *γδ*17 cells are the IL‐17 producer in the joints, although both *γδ*17 cells and Th17 cells are detected in the draining lymph nodes.[20](#imm12993-bib-0020){ref-type="ref"} IL‐17‐GFP reporter mice reveal that the V*γ*6^+^/V*δ*1^+^ cells predominantly produce IL‐17 in affected joints. Adoptive transfer of *Il1rn* ^--/--^ T cells into *scid/scid* mice shows that only a mixture of *γδ* T and CD4^+^ T cells, but not *γδ* T cells or CD4 T cells alone, can induce arthritis. Moreover, *γδ*17 cells localize in joints only when *γδ* T cells are transferred together with CD4^+^ T cells. These observations suggest that CD4^+^ T cells are required for *γδ*17 cells to localize in joints, and IL‐17 from *γδ*17 cells drives the development of arthritis. Interestingly, V*γ*6^+^ *γδ*17 cells in *Il1rn* ^−/−^ mice intrinsically express IL‐1R at high levels, indicating that these cells are ready for IL‐17 production. Hence, IL‐17 derived from different *γδ*17 cell subsets is suggested to play a crucial role in the development of arthritis in mouse models.

The mouse model of multiple sclerosis (MS), EAE is another model in which IL‐17 plays a crucial role in the pathogenesis. After induction of EAE, *γδ*17 cells as well as Th17 cells are found in the brain, with V*γ*4^+^ cells as the major component.[21](#imm12993-bib-0021){ref-type="ref"} *Tcrd* ^−/−^ mice delay the onset of disease and reduce the clinical scores. *γδ* T cells activated with IL‐1*β* and IL‐23 promote IL‐17 production by CD4^+^ T cells *in vitro* and co‐transfer of CD4^+^ and *γδ* T cells promote development of EAE, suggesting that *γδ*17 cells act in an amplification loop for IL‐17 production by Th17 cells.[21](#imm12993-bib-0021){ref-type="ref"} Interleukin‐23‐activated *γδ* T cells also prevent regulatory T‐cell function, resulting in the enhancement of *αβ* T‐cell responses and EAE development.[61](#imm12993-bib-0061){ref-type="ref"}

A pathogenic role for *γδ*17 cells is implicated in psoriasis. V*γ*5^+^/V*δ*1^+^ *γδ* T cells, also called dendritic epidermal T cells, uniquely residing in epidermis produce IFN‐*γ* and participate in immunosurveillance.[62](#imm12993-bib-0062){ref-type="ref"} On the other hand, dermis contains V*γ*4^+^ and V*γ*6^+^ subsets responsible for IL‐17 production. The pathogenicity of *γδ*17 cells in psoriasis is well studied in a mouse model of psoriasis, IMQ‐induced dermatitis.[9](#imm12993-bib-0009){ref-type="ref"}, [23](#imm12993-bib-0023){ref-type="ref"} Imiquimod is a Toll‐like receptor‐7/8 agonist and induces IL‐17‐dependent psoriasiform dermatitis by inducing IL‐23.[63](#imm12993-bib-0063){ref-type="ref"} The IMQ‐induced epidermal thickening is significantly decreased in *Tcrd* ^--/--^ mice, but not in *Tcrb* ^--/--^ mice.[9](#imm12993-bib-0009){ref-type="ref"} Development of dermatitis is also suppressed by the deficiency of innate lymphoid cells (ILCs), suggesting that *γδ*17 cells and IL‐17‐producing group 3 ILCs (ILC3s) are responsible for the development of psoriasiform dermatitis in mice.[9](#imm12993-bib-0009){ref-type="ref"}, [23](#imm12993-bib-0023){ref-type="ref"} Both V*γ*4^+^ and V*γ*6^+^ subsets produce IL‐17 after IMQ treatment of the skin.[35](#imm12993-bib-0035){ref-type="ref"} Skin inflammation after IMQ treatment is significantly attenuated in *Sox4* ^−/−^ mice, in which dermal V*γ*4^+^ but not dermal V*γ*6^+^ *γδ* T cells are greatly reduced.[42](#imm12993-bib-0042){ref-type="ref"} Congenic CD45.1^+^ (B6.SJL) mice with naturally occurring *Sox13* mutation, in which dermal V*γ*4^+^ *γδ*17 cell development is defective, develop attenuated ear skin inflammation with less acanthosis and fewer epidermal neutrophil pustules upon treatment with IMQ.[64](#imm12993-bib-0064){ref-type="ref"} However, both wild‐type bone marrow cell‐reconstituted mice and neonatal thymocytes plus CD45.1^+^(B6.SJL) bone marrow cell‐reconstituted mice (in which V*γ*4^+^ and V*γ*6^+^ cells are predominant, respectively) similarly develop epidermal thickening with increased dermal *γδ*17 cells and neutrophil infiltration, suggesting that both *γδ*17 subsets induce IMQ‐induced dermatitis.[35](#imm12993-bib-0035){ref-type="ref"} Interleukin‐17F and IL‐22 from *γδ* T cells are also pathogenic in IMQ‐induced dermatitis.[9](#imm12993-bib-0009){ref-type="ref"} Interleukin‐23‐induced skin inflammation is another model of psoriasis. The IL‐17‐producing dermal cells are significantly reduced in *Tcrd* ^−/−^ mice accompanied with less skin inflammation and acanthosis, whereas *Tcra* ^−/−^ mice normally develop dermatitis,[23](#imm12993-bib-0023){ref-type="ref"} suggesting that *γδ*17 cells play major roles in the pathogenesis of psoriatic dermatitis in this model. The involvement of *γδ*17 cells in the development of psoriasiform dermatitis suggests that innate immune responses rather than an autoimmune reaction are important for the development of psoriatic dermatitis.

The involvement of V*γ*6^+^ *γδ*17 cells in the pathogenesis of uveoretinitis in *Aire*‐deficient mice, a model of autoimmune polyendocrinopathy--candidiasis--ectodermal dystrophy (APCED), is suggested, because V*γ*6^+^ *γδ*17 thymocytes are expanded due to high levels of IL‐7 expression in *Aire* ^−/−^ medullary thymic epithelial cells.[44](#imm12993-bib-0044){ref-type="ref"} Importantly, expansion of IL‐17‐producing V*γ*9^+^/V*δ*2^+^ *γδ* T cells is observed in APCED patients, suggesting the involvement of *γδ*17 cells in these patients. *γδ*17 cells are also implicated in the pathogenesis of spondyloarthritis; the CD27^−^ *γδ* T‐cell population is increased in the Achilles tendon after over‐expression of IL‐23, which induces spondyloarthritis‐like enthesitis in mice.[65](#imm12993-bib-0065){ref-type="ref"} The V*γ*4^+^ subset produces IL‐17 in the skin grafts and in the host epidermis around grafts, suggesting the involvement in skin graft rejection.[66](#imm12993-bib-0066){ref-type="ref"} V*γ*4^+^cell‐derived IL‐17 promotes the accumulation of mature dendritic cells in the draining lymph nodes to subsequently increase Th17 cells after skin graft transplantation.[66](#imm12993-bib-0066){ref-type="ref"}

Migration of *γδ*17 cells to inflammatory sites {#imm12993-sec-0005}
===============================================

Trafficking of *γδ*17 cells to the inflammatory sites is important for the development of inflammation. Naive *αβ* T cells express a chemokine receptor CCR7, which is important for homeostatic circulation; its expression is down‐regulated during differentiation and the inflammatory chemokine receptor CCR6 is induced on Th17 cells instead. CCR6^+^ Th17 cells are recruited by CCL20 to cause inflammation, as shown in SKG mice[67](#imm12993-bib-0067){ref-type="ref"} and the EAE model.[68](#imm12993-bib-0068){ref-type="ref"}, [69](#imm12993-bib-0069){ref-type="ref"} On the other hand, a gene array analysis shows that the expression of chemokine receptors such as CCR6, CCR2 and CXCR6 is already up‐regulated in *γδ*17 cells during thymic development.[34](#imm12993-bib-0034){ref-type="ref"} Recent studies have indicated that the CCL20--CCR6 axis is mainly required for *γδ*17 cell recruitment into homeostatic sites such as dermis,[70](#imm12993-bib-0070){ref-type="ref"} whereas the CCL2--CCR2 axis recruits *γδ*17 cells into inflammatory sites, including psoriatic skin,[71](#imm12993-bib-0071){ref-type="ref"} arthritic joints,[20](#imm12993-bib-0020){ref-type="ref"} central nervous system in EAE, infected mucosal tissues and tumours.[70](#imm12993-bib-0070){ref-type="ref"} Interestingly, *γδ*17 cells constitutively express both CCR2 and CCR6, but down‐regulate CCR6 expression after inflammation.[70](#imm12993-bib-0070){ref-type="ref"} This is consistent with the 'ready‐to‐go' nature of *γδ*17 cells and suggests a *γδ*17 cell‐recruiting mechanism in which *γδ*17 cells are released from the tissue‐specific harness to migrate into inflammatory sites by reducing the tissue‐specific homing receptor.

*γδ*17 cells in tumours {#imm12993-sec-0006}
=======================

Pro‐tumour function of *γδ*17 cells has been demonstrated in several cancer models, including a breast cancer metastasis model[72](#imm12993-bib-0072){ref-type="ref"} and an ovarian cancer model,[73](#imm12993-bib-0073){ref-type="ref"} and the roles of *γδ*17 cells in the development of tumours have been reviewed elsewhere.[74](#imm12993-bib-0074){ref-type="ref"} Abundant *γδ*17 cell infiltration accompanied by immunosuppressive myeloid‐derived suppressor cells is found in human colorectal cancer with positive correlation with advanced tumour clinicopathological features, suggesting that *γδ*17 cells induce myeloid‐derived suppressor cell‐mediated immunosuppression.[75](#imm12993-bib-0075){ref-type="ref"} On the other hand, anti‐tumour function of *γδ*17 cells after therapeutic treatment has also been reported. *γδ*17 cells infiltration is observed when bladder cancer is treated by intravesical injection of *Mycobacterium* bovis bacillus Calmette--Guérin, (BCG) and these cells are protective against tumour development by recruiting neutrophils.[76](#imm12993-bib-0076){ref-type="ref"} Moreover, *γδ*17 cell infiltration in epithelial tumours is observed after chemotherapy and *γδ*17 cells enhance the recruitment of IFN‐*γ*‐producing CD8^+^ T cells that mediate the anti‐tumour function.[77](#imm12993-bib-0077){ref-type="ref"}

*γδ*17 cells in pathogen clearance {#imm12993-sec-0007}
==================================

Interleukin‐17 plays protective roles against bacterial and fungal infection by recruiting neutrophils, activating T cells and inducing antimicrobial peptides and inflammatory cytokines.[1](#imm12993-bib-0001){ref-type="ref"}, [4](#imm12993-bib-0004){ref-type="ref"}, [5](#imm12993-bib-0005){ref-type="ref"} *γδ*17 cells produce much more IL‐17 than Th17 cells after *Mycobacterium tuberculosis* [78](#imm12993-bib-0078){ref-type="ref"} or *Mycobacterium bovis* BCG infection.[79](#imm12993-bib-0079){ref-type="ref"} Expression of IL‐17 is detected in lungs from the first day after infection with BCG and induces not only neutrophil‐mediated inflammation but also granuloma formation.[79](#imm12993-bib-0079){ref-type="ref"} Dermal *γδ* T cells also produce IL‐17 at the first day after intradermal BCG infection and induce neutrophil recruitment and antigen‐specific CD4^+^ T‐cell expansion.[80](#imm12993-bib-0080){ref-type="ref"} Rapid IL‐17 production by V*δ*1^+^ T cells is also observed in the peritoneum after intraperitoneal infection with *Escherichia coli*, followed by neutrophil recruitment.[81](#imm12993-bib-0081){ref-type="ref"} *γδ*17 cells are also found in the liver after *Listeria monocytogenes* infection[82](#imm12993-bib-0082){ref-type="ref"} and in lungs after *Klebsiella pneumoniae* infection.[83](#imm12993-bib-0083){ref-type="ref"}

*γδ*17 cells produce IL‐17 rapidly after infection with fungi, such as *Candida albicans*. *γδ*17 cells are observed in lungs after systemic *C. albicans* infection, and both *Il17* ^−/−^ and *Tcrd* ^−/−^ mice are defective in neutrophil recruitment and fungal clearance.[84](#imm12993-bib-0084){ref-type="ref"} Interleukin‐17 is produced in tongue‐resident *γδ* T cells as well as CD3^+^ CD4^+^ CD44^hi^ TCR‐*β* ^+^ CCR6^+^ natural Th17 cells within 1--2 days after oral *C. albicans* infection.[85](#imm12993-bib-0085){ref-type="ref"} As IL‐17 production in *γδ* T cells is found at the early stage after infection, *γδ*17 cells are suggested to play an important role in early host defence before establishment of acquired immunity. In humans, patients carrying mutations in either STAT3, IL‐17RA, or IL‐17F or producing anti‐IL‐17F autoantibodies are also highly susceptible to skin infection with *Staphylococcus aureus* and *C. albicans*.[86](#imm12993-bib-0086){ref-type="ref"}, [87](#imm12993-bib-0087){ref-type="ref"} However, the involvement of *γδ*17 cells in host defence in humans against these pathogens remains to be elucidated.

Recently, pathogen‐specific memory *γδ* T cells have been implicated in several infection models. Memory *γδ* T cells are elicited in mesenteric lymph nodes after oral *L. monocytogenes* infection and contribute to clearance of the bacteria by promptly producing IL‐17 after secondary infection.[88](#imm12993-bib-0088){ref-type="ref"}, [89](#imm12993-bib-0089){ref-type="ref"} Interestingly, both V*γ*4^+^ and V*γ*1^−^ V*γ*4^−^ *γδ* (potentially V*γ*6^+^) T cells produce IL‐17 in the lungs as early as 2 hr after *Bordetella pertussis* infection, whereas the exclusively V*γ*4^+^ subset expands in lungs 14 days after infection. Moreover, lung V*γ*4^+^ *γδ* T cells produce IL‐17 in response to heat‐killed *B. pertussis* in the presence of antigen‐presenting cells.[90](#imm12993-bib-0090){ref-type="ref"} These studies suggest that V*γ*4^+^ T cells, but not V*γ*6^+^ T cells, behave like adaptive immunological memory cells in a pathogen‐specific manner.

*γδ*17 cells in human inflammatory diseases {#imm12993-sec-0008}
===========================================

Although it has been thought that psoriasis is caused by an autoimmune mechanism,[91](#imm12993-bib-0091){ref-type="ref"} recent studies using mouse models suggest the involvement of innate immunity.[92](#imm12993-bib-0092){ref-type="ref"} High frequency of *γδ* T cells is detected in psoriasiform dermal lesions in mice induced by IMQ, and these cells produce IL‐17 through stimulation with IL‐23,[23](#imm12993-bib-0023){ref-type="ref"} indicating the innate immune nature of the disease. *γδ* T cells, especially V*γ*9^+^V*δ*2^+^ cells which can produce IL‐17, are also accumulated in the skin of patients with psoriasis.[93](#imm12993-bib-0093){ref-type="ref"} In this report, however, V*γ*9^+^V*δ*2^+^ cells were activated to produce cytokines from keratinocytes by the specific antigen, suggesting that recognition of specific antigens may be important for the development of psoriasis. Because Th17 cells[94](#imm12993-bib-0094){ref-type="ref"} and ILC3s[95](#imm12993-bib-0095){ref-type="ref"} as well as *γδ*17 cells[91](#imm12993-bib-0091){ref-type="ref"} are also detected in the psoriatic skin, the involvement of autoimmunity and the main source of IL‐17 during the development of psoriasis still remain obscure in humans.

Recently, several antibodies targeting IL‐17 and its receptor have been approved or are in clinical trials for the treatment of psoriasis and psoriatic arthritis.[96](#imm12993-bib-0096){ref-type="ref"} Secukinumab, an anti‐IL‐17 antibody, has been approved in Japan in 2014 and by the US Food and Drug Administration in 2015 for the treatment of psoriasis and psoriatic arthritis. Treatment with secukinumab for psoriasis patients in a phase III trial shows that more than half of the patients accomplish almost complete remission after 12 weeks of treatment, as determined by the Psoriasis Area and Severity Index (PASI 90), and show better efficacy than a tumour necrosis factor inhibitor (etanercept).[11](#imm12993-bib-0011){ref-type="ref"} Ixekizumab, another monoclonal antibody against IL‐17, and Brodalumab, a monoclonal antibody against IL‐17RA, are also effective for the treatment of psoriasis in phase III trials[12](#imm12993-bib-0012){ref-type="ref"}, [13](#imm12993-bib-0013){ref-type="ref"} and approved for the treatment of psoriasis. Secukinumab has also been approved for the treatment of ankylosing spondylitis.[97](#imm12993-bib-0097){ref-type="ref"}

As described, the importance of IL‐17 in the development of rheumatoid arthritis (RA) is suggested in mouse models and *γδ*17 cells are accumulated in arthritic joints,[7](#imm12993-bib-0007){ref-type="ref"}, [20](#imm12993-bib-0020){ref-type="ref"}, [22](#imm12993-bib-0022){ref-type="ref"}, [24](#imm12993-bib-0024){ref-type="ref"} but the importance of *γδ*17 cells in patients with RA is controversial. A recent report shows that V*δ*2^+^ *γδ* T cells accumulate in the synovium of patients with RA and produce high levels of IL‐17 as well as IFN‐*γ*.[98](#imm12993-bib-0098){ref-type="ref"} However, the predominance of IFN‐*γ*‐producing *γδ* T cells instead of *γδ*17 cells in affected joints is reported elsewhere.[24](#imm12993-bib-0024){ref-type="ref"} This discrepancy may result from the differences of medical treatment and/or stages of RA. Because the efficacy of anti‐IL‐17 treatment of RA is moderate except for some patients with specific HLA types,[99](#imm12993-bib-0099){ref-type="ref"}, [100](#imm12993-bib-0100){ref-type="ref"} *γδ*17 cells may not play crucial roles in the development of RA in humans. Further studies in patients with RA are necessary.

Elevated IL‐17 expression in *γδ* T cells, but not CD4^+^ T cells, was found in patients with systemic juvenile idiopathic arthritis,[101](#imm12993-bib-0101){ref-type="ref"} and IL‐17 production was detected in CD161^hi^ CCR6^+^ *γδ* T cells in cerebrospinal fluid of patients with MS.[102](#imm12993-bib-0102){ref-type="ref"} Treatment of patients with MS with secukinumab non‐significantly reduced the number of combined unique active lesions and significantly reduced the number of cumulative new gadolinium‐enhancing T1 lesions by 67%.[103](#imm12993-bib-0103){ref-type="ref"} Further studies are necessary to elucidate the role of *γδ*17 cells in the development of these diseases.

Concluding remarks {#imm12993-sec-0009}
==================

In this review, we discussed the development and the function of *γδ*17 cells and the roles of *γδ*17 cells in inflammatory/autoimmune diseases and host defence against pathogens. However, several important questions still remain to be elucidated. The function of TCR signalling in the thymic development of *γδ*17 and the functional roles of TCR signalling in the periphery upon infection and inflammation are not completely elucidated. Elucidation of epigenetic modifications of genes in 'natural' and 'inducible' *γδ*17 cells may provide important information. Discovery of *γδ*17 cell‐specific markers may provide a more efficient approach to induce *γδ*17 cell‐specific dysfunction in inflammatory diseases without affecting systemic Th17 cells. Most importantly, it is not clear how well mouse disease models represent the pathogenesis of human diseases, especially those of psoriasis, MS and RA. In the case of psoriasis, inhibition of IL‐17 signalling efficiently cures the symptoms both in psoriasis patients and IMQ‐induced psoriasis models, suggesting that *γδ*17 cells play important roles in both humans and mice. However, in MS and RA, in which the involvement of *γδ*17 is suggested by mouse models, the therapeutic effects of anti‐IL‐17 are not so drastic as indicated by these models, suggesting that the pathogenic mechanisms may be different in some parts between diseases in humans and mice. Clearly, further analysis of pathogenic mechanisms in patients is necessary to explain this discrepancy.
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